1593-60-8Relevant articles and documents
Iron(ii)-catalyzed intermolecular aziridination of alkenes employing hydroxylamine derivatives as clean nitrene sources
Berhal, Farouk,Grimaud, Laurence,Kirby, Georgina,Prestat, Guillaume,Vitale, Maxime R.
supporting information, p. 9428 - 9432 (2021/12/09)
The iron-catalyzed intermolecular aziridination of alkenes with hydroxylamine derivatives is described. Using simple iron(ii) sources and readily available ligands, the formal (2 + 1) cycloaddition process proved to be efficient on both styrenes and aliphatic alkenes, providing access to a wide range of aziridines. In these particularly sustainable reaction conditions, yields up to 89% could be obtained, with a catalyst loading which could be lowered to 5 mol% when the reaction was performed on large scale. Preliminary mechanistic studies suggest that both concerted and stepwise pathways are operating in this transformation. This journal is
An Effective Method for the Synthesis of 1,3-Dihydro-2H-indazoles via N-N Bond Formation
Zhang, Xiaoke,Pan, Yang,Liang, Peng,Ma, Xiaofeng,Jiao, Wei,Shao, Huawu
supporting information, p. 5552 - 5557 (2019/11/22)
The [4+1] cycloaddition reaction of bifunctional amino reagents has been achieved with in situ formed aza-ortho-quinone methides. Specifically, N-(tosyloxy)carbamates were used as an N1 synthon and bifunctional amino reagents for this transformation, which provides a metal-free, catalyst-free, and oxidant-free strategy to form nitrogen-nitrogen bonds. (Figure presented.).
Thienopyrimidine derivative, preparation method thereof and application thereof in medicines
-
Paragraph 0175; 0176; 0177, (2016/10/17)
The invention provides a thienopyrimidine derivative, a preparation method thereof and an application thereof in medicines. Specifically, the invention relates to a compound represented by a formula I, wherein the radicals are defined in the description. The compound is effective tyrosine kinase inhibitors in one category, and is particularly suitable for being used as an EGFR and/or HER2 inhibitor.